231 results about "Ceramide AP" patented technology

Provided is a ceramide emulsion containing the following components (A), (B) and (C) and not containing an acrylic acid polymer or a phospholipid: (A) sphingosines represented by Formula (1): (wherein R1 represents a hydrocarbon group having 4 to 30 carbon atoms which is optionally substituted with a hydroxyl group and the like; Y represents CH2, CH or O; X1, X2 and X3 represent H, a hydroxyl group or an acetoxy group; X4 represents H, an acetyl group or a glyceryl group or, together with an adjacent O atom, forms an oxo group; R2 and R3 represent H, a hydroxyl group, a hydroxymethyl group or an acetoxymethyl group; groups “R”s are H or an amidino group or represent a hydrocarbon group having 1 to 8 carbon atoms which may have a substituent such as a hydroxyl group and the like; and “a” is 2 or 3), (B) an acidic compound selected from inorganic acids and organic acids having a molecular weight of 200 or less, and (C) ceramides represented by Formula (2): (wherein R7 represents a hydrocarbon group having 4 to 30 carbon atoms which is optionally substituted with a hydroxyl group and the like; Z represents CH2, CH or O; X5, X6 and X7 represent H, a hydroxyl group or an acetoxy group, X4 represents H, an acetyl group or a glyceryl group or, together with an adjacent O atom, forms an oxo group; R8 and R9 represent H, a hydroxyl group, a hydroxymethyl group or an acetoxymethyl group; R10 represents a hydrocarbon group having 5 to 60 carbon atoms which is optionally substituted with a hydroxyl group and the like; and R11 represents H or a hydrocarbon group having 1 to 8 carbon atoms which optionally have a substituent such as a hydroxyl group and the like).

The invention discloses a metabolic marker combination for evaluating the risks of cardiovascular and cerebrovascular disease of a subject. The metabolic marker combination comprises ceramide Cer d18:1 / 16:0, ceramide Cer d18:1 / 18:0, ceramide Cer d18:1 / 24:0, phenylacetyl glutamine, trimethylamine, glycine betaine and choline. The cardiovascular and cerebrovascular diseases are selected from coronary heart disease, atherosclerosis, atrial fibrillation and heart failure. The metabolic marker combination disclosed by the invention has the advantages of high sensitivity, good specificity, quantification, high detection flux and the like in the aspect of evaluating or predicting the risks of cardiovascular and cerebrovascular diseases.

The invention provides a biomarker for diagnosing white matter lesion and application thereof. The biomarker is cholesterol-alpha-D-glucoside. The biomarker cholesterol-alpha-D-glucoside is combined with 6Z,9Z,20-eicosatrienoic acid, ceramide (m18:1(4E) / 24:1(15Z)), ephedrine A, cucurbitacine E, cholesteryl ester 22:6 or ceramide (d18:0 / 24:1(15Z)) to judge whether white matter lesion exists or not. The biomarker for diagnosing the white matter lesion is used for preparing a detection reagent for diagnosing the white matter lesion, and is beneficial for diagnosing whether the white matter lesion tends to exist or not and preventing the white matter lesion in advance.

A composition and process for treating a keratinous substrate involving contacting the keratinous substrate with a composition containing: a) at least one quaternary ammonium polymer; b) at least one fatty quaternary agent; c) at least one nonionic surfactant; and d) optionally, at least one ceramide, and wherein the composition is substantially anhydrous.

The invention provides a biomarker for diagnosing white matter lesion and application thereof, and the biomarker is 6Z, 9Z, 20-eicosatrienoic acid. The biomarker 6Z, 9Z, 20-eicosatrienoic acid is combined with ceramide (m18: 1 (4E) / 24: 1 (15Z)), ephedrine A, cucurbitacine E, cholesteryl ester 22: 6 or ceramide (d18: 0 / 24: 1 (15Z)) for judging whether white matter lesion exists or not. The biomarker for diagnosing the white matter lesion is used for preparing a diagnostic reagent for predicting or diagnosing the white matter lesion, and is beneficial for diagnosing whether the white matter lesion tends to exist or not and preventing the white matter lesion in advance.

A method of treating polycystic kidney disease in a subject comprises administering to the subject an effective amount of a compound represented by Structural Formula (1): or a pharmaceutically acceptable salt thereof.

The invention belongs to the technical field of medicines, and relates to a sebum liposome and a preparation method of the same. The sebum liposome comprises ceramide, phospholipid, free fatty acids and cholesterol, wherein the ceramide is a corn extract, namely, corn ceramide, the phospholipids is soya bean lecithin, and the free fatty acids comprise palmitic acid, linoleic acid and oleic acid; the molar ratio of the ceramide to the phospholipid is (1:1)-(9:1), and preferably 2: 1; and the molar ratio of the ceramide or the phospholipid to cholesterol is not greater than 1 / 3, and preferably not greater than 1 / 5. A novel medicine-loading system for the sebum liposome is put forward for the first time; and the system can be used for external preparations, has the advantages of being high in medicine-loading capacity and good in stability, as well as is high in affinity with the skin, and capable of reducing the irritation of the external preparations, enhancing the union of the broken skin, and providing a better application prospect for the external medicine preparations.

The invention discloses ceramide-containing tea seed extract and a preparation method thereof. The preparation method comprises the following steps of: crushing raw materials, extracting by using water or low-carbon alcohol, and recycling an extraction solvent from the obtained extracting solution so as to obtain extract, wherein the raw materials are seeds of theaceae camellia plants, namely camellia oleifera abel, camellia or common camellia, or residues of the seeds of the plants subjected to oil component extraction; adding alkaline solution into the extract, and hydrolyzing at the temperature of between 10 and 80 DEG C for 0.5 to 20 hours; and separating the obtained hydrolyzate by using a macroporous resin column, performing chromatography through a silica gel column or a sephadex column, eluting by using 40 to 60 volume percent aqueous solution of methanol or ethanol, performing thin layer chromatography, collecting fractions, mixing the fractions, and drying to obtain the ceramide-containing tea seed extract. The raw materials are readily available and the method is environmentally-friendly; the preparation process is simple; the product quality is stable; the production cost is low; and the content of ceramide in the extract is high.

The present disclosure relates to bi-phase micellar liquid products that include ceramides and other components that are beneficial to the skin. In particular, the products include: (a) a fatty phase comprising one or more fatty compounds and one or more silicones; and (b) an aqueous phase comprising one or more ceramides, one or more water-soluble solvents, one or more surfactants, and water. The products are particularly unique because the ceramides are solubilized in the aqueous phase of the products. In addition to being useful for cleansing the skin, the products support natural lipid barrier function of the skin and improve skin hydration.